Synthesia In Profit

9 January 1995

Synthesia Semtin, a producer of pharmaceuticals, organic chemicals, pigments and dyes in the Czech capital Prague, is expected to achieve pretax profits of 630 million koruna ($22.3 million) for 1994, reports the CTK news agency's Business News.

These results will be close to company forecasts. Sales in the first nine months of 1994 totalled 4 billion koruna, or 82% of the target for the year, representing growth of 15% compared with 1993. Exports increased by 25% in the first nine months of last year, accounting for 52% of total sales. Synthesia has recently started to sell its products on the US market, in addition to its European business. The company currently employs a workforce of 7,100 and is looking to take on 300 more workers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight